MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

About this update from Mira Pharmaceuticals, Inc.

[{"type":"text","content":"MIAMI, FL / ACCESSWIRE / August 19, 2024 / MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) \"MIRA\" or the \"Company\"), a leading pre-clinical-stage pharmaceutical company, is pleased to provide a comprehensive update on its recent achievements and scientific advancements as it nears a crucial milestone: the submission of its Investigational New Drug (IND) application by the end of the year. This update highlights the company's strategic progress, significant scientific breakthroughs, and the expertise driving its innovative drug candidates toward clinical trials.Recent Company HighlightsLeadership Enhancement with Dr. Itzchak AngelMIRA has strengthened its leadership by appointing Dr. Itzchak Angel as Chief Scientific Advisor. With over 40 years of experience, including a distinguished career at Synthelabo (now Sanofi-Aventis), Dr. Angel was instrumental in the development and regulatory approval of several key drugs, such as Ambien, Xatral and Mizolen. His expertise in advancing drug candidates from early research through clinical trials is now guiding MIRA's pipeline​.Scientific Progress with Ketamir-2MIRA has made significant strides with its novel oral ketamine analog, Ketamir-2. The Company has established a robust manufacturing process for the compound, which allows large-scale, high-quality synthesis with low cost of goods. Recent preclinical studies have demonstrated that Ketamir-2 offers a superior safety profile compared to traditional ketamine, notably avoiding hyper-locomotor activity-a behavior linked to psychotic symptoms-thereby positioning it as a potentially safer option for mental health treatments. The Company has further explored the pharmacological profile of the compound in animal models of anxiety and depression. Significant dose-depended effects were observed upon oral administration of the compound to mice in models such as Elevated Plus Maze, Open Filed and Forced Swim Tests.The Company's key discoveries include Ketamir-2's non-substrate status for P-glycoprotein (P-gp), which allows for better oral absorption and improved passage through the blood-brain barrier, and potentially higher efficacy at lower doses. Further analysis has shown that Ketamir-2 selectively inhibits the NMDA receptor at the PCP-binding site with 30-50 times lower affinity than traditional ketamine, reducing the risk of side effects such...

More updates from Mira Pharmaceuticals, Inc.